EUVIMEDEUVIMED entdecken
Crossref

The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase

Seyed Amirhossein Tabatabaei Dakhili, Amanda A Greenwell, Kunyan Yang, Rabih Abou Farraj, Christina T Saed, Keshav Gopal, Jordan S F Chan, Jadin J Chahade, Farah Eaton, Crystal Lee, Carlos A Velázquez-Martínez, Peter A Crawford und 3 weitere

Diabetes · 01.01.2023 · 72 (1) · 126-134

DOI: 10.2337/db22-0221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, online erschienen am 18.10.2022. Verfasst von Seyed Amirhossein Tabatabaei Dakhili und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Antipsychotic Agents, Diabetes Mellitus, Type 2, Hyperglycemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CIHR, Institute of Nutrition, Metabolism and Diabetes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant progress in understanding the pathogenesis of type 2 diabetes (T2D), the condition remains difficult to manage. Hence, new therapeutic options targeting unique mechanisms of action are required. We have previously observed that elevated skeletal muscle succinyl CoA:3-ketoacid CoA transferase (SCOT) activity, the rate-limiting enzyme of ketone oxidation, contributes to the hyperglycemia characterizing obesity and T2D. Moreover, we identified that the typical antipsychotic agent pimozide is a SCOT inhibitor that can alleviate obesity-induced hyperglycemia. We now extend those observations here, using computer-assisted in silico modeling and in vivo pharmacology studies that highlight SCOT as a noncanonical target shared among the diphenylbutylpiperidine (DPBP) drug class, which includes penfluridol and fluspirilene. All three DPBPs tested (pimozide, penfluridol, and fluspirilene) improved glycemia in obese mice. While the canonical target of the DPBPs is the dopamine 2 receptor, studies in obese mice demonstrated that acute or chronic treatment with a structurally unrelated antipsychotic dopamine 2 receptor antagonist, lurasidone, was devoid of glucose-lowering actions. We further observed that the DPBPs improved glycemia in a SCOT-dependent manner in skeletal muscle, suggesting that this older class of antipsychotic agents may have utility in being repurposed for the treatment of T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsDiabetes Mellitus, Type 2HyperglycemiaAnimalsMiceCoenzyme A-TransferasesDopamineFluspirileneMice, ObesePenfluridolPimozideReceptors, DopamineAcyl Coenzyme A

Substanzen

Antipsychotic AgentsCoenzyme A-TransferasesDopamineFluspirilenePenfluridolPimozideReceptors, Dopaminesuccinyl-coenzyme AAcyl Coenzyme A

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
  • Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
  • Division of Molecular Medicine, Department of Medicine, Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN.
  • Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.

ORCID-Profile: John R Ussher

Förderung

  • CIHR
  • Institute of Nutrition, Metabolism and Diabetes

Zitieren

APA

Tabatabaei Dakhili, S. A., Greenwell, A. A., Yang, K., Abou Farraj, R., Saed, C. T., Gopal, K., Chan, J. S. F., Chahade, J. J., Eaton, F., Lee, C., Velázquez-Martínez, C. A., Crawford, P. A., Glover, J. N. M., Al Batran, R., & Ussher, J. R. (2023). The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes, 72(1), 126-134. https://doi.org/10.2337/db22-0221

Vancouver

Tabatabaei Dakhili SA, Greenwell AA, Yang K, Abou Farraj R, Saed CT, Gopal K, et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes. 2023;72(1):126-134. doi:10.2337/db22-0221

BibTeX
@article{TabatabaeiDakhili2023,
  author = {Tabatabaei Dakhili, Seyed Amirhossein and Greenwell, Amanda A and Yang, Kunyan and Abou Farraj, Rabih and Saed, Christina T and Gopal, Keshav and Chan, Jordan S F and Chahade, Jadin J and Eaton, Farah and Lee, Crystal and Velázquez-Martínez, Carlos A and Crawford, Peter A and Glover, J N Mark and Al Batran, Rami and Ussher, John R},
  title = {The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase},
  journal = {Diabetes},
  year = {2023},
  volume = {72},
  number = {1},
  pages = {126--134},
  doi = {10.2337/db22-0221}
}
Kostenlos starten →